Physician profile
James Kayvanfar
NPI 1548288194
$13,339.52
in general payments reported to CMS, 2019-2025
29 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,108 · 2020: $610 · 2021: $2,735 · 2022: $1,507 · 2023: $1,542 · 2024: $720 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155 · Education: $170 · Travel and Lodging: $53.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.31 |
| Education | $170.43 |
| Travel and Lodging | $53.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $3,125.05 | 2019-2025 | |
| Radius Health, INC. | $2,544.78 | 2019-2025 | Tymlos |
| Medtronic, INC. | $1,814.93 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Bio-Flek |
| Alphatec Spine, INC | $1,756.40 | 2021 | |
| Amgen INC. | $1,310.93 | 2019-2024 | Evenity, Prolia |
| Zimmer Biomet Holdings, INC. | $689.69 | 2023-2025 | Persona, Oxford, Accufill |
| Medtronic USA, INC. | $346.67 | 2019 | |
| Smith+Nephew, INC. | $281.64 | 2022-2023 | Journey II Xr, Real Intelligence, Journey II |
| Si-Bone, INC. | $227.46 | 2021-2023 | |
| Stryker Corporation | $218.87 | 2019-2020 | |
| Baylis Medical Company INC | $160.88 | 2019 | |
| Team_makena_llc | $140.14 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $138.88 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $123.95 | 2021 | |
| Merit Medical Systems INC | $70.68 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heraeus Medical, LLC. | $49.28 | 2021-2022 | |
| Medical Device Business Services, INC. | $48.56 | 2019 | |
| Alvogen INC | $41.86 | 2025 | Teriparatide |
| Vertex Pharmaceuticals Incorporated | $31.20 | 2025 | |
| Ethicon US, LLC | $29.22 | 2022 | |
| Boston Scientific Corporation | $24.71 | 2020 | |
| Merck Sharp & Dohme LLC | $23.72 | 2024 | Bridion |
| Titan Spine, LLC | $23.45 | 2019 | |
| Axogen | $23.38 | 2019 | |
| Heron Therapeutics, INC. | $22.50 | 2022 | |
| Fidia Pharma USA INC. | $22.11 | 2019 | |
| Convatec INC. | $20.76 | 2024 | |
| Lilly USA, LLC | $14.04 | 2019 | |
| Dynasplint Systems INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kayvanfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.